Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04620837
Other study ID # NCC-04254
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date November 1, 2020
Est. completion date December 31, 2023

Study information

Verified date October 2020
Source Chinese Academy of Medical Sciences
Contact Yuankai Shi, MD
Phone 86-10-87788293
Email syuankaipumc@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To show that maintenance therapy with Tislelizumab plus Anlotinib will prolong Progression Free Survival in subjects with extensive stage disease small cell lung cancer who have completed first line chemotherapy.


Description:

Most patients with extensive disease small cell lung cancer (ED-SCLC) respond to first line(1L) platinum-based chemotherapy; however, responses are not durable and prognosis is poor. Currently no maintenance treatments are approved in SCLC to prolong the durability of efficacy achieved with 1L chemotherapy. Immuno-oncology agents have demonstrated efficacy in the treatment of ED-SCLC when administered across different lines of therapy. Tislelizumab (Anti-PD-1 antibody) Combine Etoposide+ platinum (EP) had improved median Overall survival (mOS ) to 15.6m of 1L ED-SCLC in the Rationale 206 study. Anlotinib ( RTKi ) had significantly improved PFS & OS of 3L(third line) ED-SCLC in the ALTER 1202. This phase II study is designed to explore the effect and safety of the combination as maintenance therapy for ED-SCLC after 1L chemotherapy


Recruitment information / eligibility

Status Recruiting
Enrollment 25
Est. completion date December 31, 2023
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Subjects with histologically or cytologically confirmed extensive stage disease SCLC - Ongoing response of stable disease or better following 4 cycles of platinum-based first line chemotherapy - Patients should enter the study within 5 weeks after the completion of cycle 4 chemotherapy (the last dose). - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Extensive-stage disease at diagnosis - Patients must have received 4 cycles of platinum-containing chemotherapy and must be at the level of complete remission (CR), partial remission (PR), or disease stabilization (SD) at the time of completion of chemotherapy. According to the The National Comprehensive Cancer Network (NCCN) guidelines, acceptable combination therapy includes cisplatin or carboplatin plus etoposide or irinotecan. - The woman patients of childbearing age who must agree to take contraceptive methods (e.g. intrauterine device, contraceptive pill or condom) during the research and within another 6 months after it; who are not in the lactation period and examined as negative in blood serum test or urine pregnancy test within 7 days before the research; The man patients who must agree to take contraceptive methods during the research and within another 6 months after it - Otherwise healthy Exclusion Criteria: - Subjects with symptomatic Central Nervous System (CNS) metastases - Subjects receiving consolidative chest radiation - Subjects with active, known, or suspected autoimmune disease are excluded Cancerous meningitis. - Pleural effusions that are not controlled by appropriate interventions - All side effects attributed to prior anti-cancer therapy must have resolved to Grade 1 or baseline - Medical history and concurrent diseases. a) Pregnant or lactating women. b) Active, known or suspected autoimmune diseases. Exclude conditions that require immunosuppressive therapy. d) Previous use of anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibodies (including Ipilimumab or any other T-cell co-stimulation or checkpoint pathway points) The antibody or drug e). The subject has interstitial lung disease, the disease has symptoms, or the disease may affect the discovery or management of suspected drug-related lung toxicity. f) Previous malignancy unless at least prior to participating in the study Completely relieved 2 years ago and requires no additional treatment during the study. g)Based on the investigator's judgment, known medical conditions increase the risk associated with participating in the study or giving the blinded study drug or affecting the interpretation of the findings. - Physical examination and laboratory tests found. a)Hepatitis B virus (HBV) surface antigen test to determine hepatitis B virus positive, or Hepatitis C virus( HCV) ribonuclease test to determine hepatitis C virus positive, or HCV antibody test showed acute or chronic infection. b) A history of HIV-positive disease is known or a history of AIDS disease is known. c) Insufficient hematopoietic function. d)Insufficient liver function. e) insufficient pancreatic function - Patients get any severe diseases or the ones that cannot be controlled take major surgical treatments, open biopsy, or get overt traumatic injury within 28 days before grouping - Patients have any habitus or medical history of hemorrhage, however severe it is; the patients who have non healing wounds, ulcer or fracture after any events with hemorrhage or bleeding (> or =CTCAE level 3) - Patients get arterial/venous thrombosis within 6 months, such as cerebrovascular accidents (including temporary ischemic stroke), deep venous thrombosis, and pulmonary embolism - Patients ever abuse psychiatric drugs and cannot abstain or who are diagnosed with mental disorder - -Patients have participated in other clinical trials of anti-tumor medicine within 4 weeks - Patients diagnosed with disease which will severely endanger the security of patients or influence the completion of this research. - Allergies and Adverse Drug Reactions: A history of allergies or hypersensitivity reactions to any study drug or other study drug component

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tislelizumab
Tislelizumab:200mg Q3W IV. There will be no dose reduction for Tislelizumab , if there is no disease progression or serious Treatment Related adverse events(TRAE) , patients will receive Tislelizumab (200mg,Q3W) until progression or death
Anlotinib hydrochloride
Anlotinib hydrochloride capsules: Capsule; specifications 12mg; oral, once a day, every 12mg, continuous medication two weeks after 1 week deactivated. Depending tolerated dose reduction. Medication process: disease control and patients can tolerate the side effects, continued drug use; researchers believe the patient is not fit to continue medication or efficacy evaluation at the end of the clinical progression of medication.

Locations

Country Name City State
China National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Chinese Academy of Medical Sciences

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of progression free survival Rate of progression free survival in 6 month 6 months
Secondary overall survival OS 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT05882058 - DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers Phase 2
Terminated NCT03963414 - A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC Phase 1
Active, not recruiting NCT04358237 - Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer. Phase 1/Phase 2
Not yet recruiting NCT06419179 - Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) Phase 2
Completed NCT02874664 - A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer Phase 1
Completed NCT02397733 - Memory Preservation of Prophylactic Cranial Irradiation With Hippocampal Avoidance (PREMER-TRIAL) N/A
Recruiting NCT01977235 - Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer Phase 2
Completed NCT00759824 - A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide Phase 2
Active, not recruiting NCT03568097 - Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer Phase 2
Withdrawn NCT02876081 - Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex Phase 2
Recruiting NCT06247605 - A Phase IIII Study of AL8326 in Small Cell Lung Cancer Phase 3
Recruiting NCT04996771 - Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer Phase 1/Phase 2
Terminated NCT03662074 - Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer Phase 2
Completed NCT03232593 - A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
Completed NCT01941316 - Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients Phase 1/Phase 2
Terminated NCT01574300 - Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network
Recruiting NCT06131840 - A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors Phase 1
Recruiting NCT05683977 - A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.
Recruiting NCT05329623 - A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants. Phase 1
Active, not recruiting NCT04902872 - Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors Phase 1/Phase 2